Loading...
Update on PARP Inhibitors in Breast Cancer
The single agent activity of PARP inhibitors (PARPi) in germline BRCA mutated (gBRCAm) breast and ovarian cancer suggests untapped potential for this new class of drug in breast cancer. The US Food and Drug Administration has approved three PARPi (olaparib, rucaparib, and niraparib) so far to treat...
Na minha lista:
| Udgivet i: | Curr Treat Options Oncol |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7430202/ https://ncbi.nlm.nih.gov/pubmed/29644491 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11864-018-0540-2 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|